Tetraphase climbs on Phase III cIAI data

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) jumped $4.81 (14%) to $38 on Thursday after IV eravacycline met the primary endpoint in the Phase III IGNITE 1

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE